SGLTR M 1000 Tablet - Strip of 10

SGLTR M 1000 Tablet is a specialized pharmaceutical formulation designed for the management of Type 2 diabetes mellitus. This medication combines two active ingredients, Remogliflozin Etabonate and Metformin, which work synergistically to control blood sugar levels effectively. The primary purpose of SGLTR M 1000 Tablet is to enhance glycemic control in adults with Type 2 diabetes, making it a vital component in diabetes management. The therapeutic category of SGLTR M 1000 Tablet falls under antidiabetic medications, specifically targeting glucose regulation through dual mechanisms. Remogliflozin Etabonate functions as a sodium-glucose cotransporter 2 (SGLT2) inhibitor, promoting the excretion of excess glucose via urine, while Metformin, a biguanide, reduces hepatic glucose production and improves insulin sensitivity. Together, these components in SGLTR M 1000 Tablet provide a comprehensive approach to managing diabetes, helping patients maintain optimal blood sugar levels and reduce the risk of complications associated with uncontrolled diabetes. The formulation is particularly beneficial for individuals who may not achieve adequate control with Metformin alone, offering an effective alternative that addresses multiple pathways involved in glucose metabolism. SGLTR M 1000 Tablet is typically prescribed as part of a broader diabetes management plan that includes dietary modifications and physical activity. By incorporating SGLTR M 1000 Tablet into their routine, patients can experience improved glycemic control and a better quality of life. Regular monitoring of blood glucose levels is essential while using SGLTR M 1000 Tablet to ensure optimal therapeutic outcomes and to adjust the treatment regimen as necessary. Overall, SGLTR M 1000 Tablet represents a significant advancement in the pharmacological management of Type 2 diabetes, providing patients with a reliable option for achieving their health goals.